Abstract
Summary
The Asia-Pacific non-Hodgkin lymphoma diagnostics market is projected to register a substantial CAGR of 8.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Asia-Pacific Non-Hodgkin Lymphoma Diagnostics Market, By Test Type (Imaging, Biopsy, Immunohistochemistry, Biomarker Test, Genetic Test, Cytogenetics, Lumbar Puncture (Spinal Tap), Blood Test and Cytochemistry), Cancer Stage (Stage IV, Stage III, Stage II, Stage I, and Stage 0), Tumor Type (Aggressive Lymphomas and Indolent Lymphomas), Product (Instrument Based Products, Platform Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of Asia-Pacific non-Hodgkin lymphoma diagnostics market are:
• Increased growth in the prevalence of non-Hodgkin lymphoma
• Advancement in artificial intelligence in the diagnosis of non-Hodgkin lymphoma
Market Players:
Some of the major players operating in the Asia-Pacific Non-Hodgkin lymphoma diagnostics market are:
• CANON MEDICAL SYSTEMS CORPORATION
• Koninklijke Philips N.V.
• Siemens Healthcare GmbH
• Danaher.
• Bio-Rad Laboratories, Inc.
• General Electric Company
• Sysmex Corporation
• Grail
• F. Hoffmann-La Roche
• Neusoft Corporation
• Agilent Technologies, Inc.
• NeoGenomics Laboratories
• Hologic, Inc
• Integrated DNA Technologies, Inc.
• CENTOGENE N.V.
• Merit Medical Systems
• Invitae Corporation
• PerkinElmer Inc.
• QIAGEN
• GeneDx, LLC
Table of Contents
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 84
1.4 LIMITATIONS 86
1.5 MARKETS COVERED 87
2 MARKET SEGMENTATION 90
2.1 MARKETS COVERED 90
2.2 GEOGRAPHICAL SCOPE 91
2.3 YEARS CONSIDERED FOR THE STUDY 92
2.4 CURRENCY AND PRICING 92
2.5 DBMR TRIPOD DATA VALIDATION MODEL 93
2.6 MULTIVARIATE MODELLING 96
2.7 PRODUCT TYPE LIFELINE CURVE 96
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
2.9 DBMR MARKET POSITION GRID 98
2.10 MARKET APPLICATION COVERAGE GRID 99
2.11 VENDOR SHARE ANALYSIS 100
2.12 SECONDARY SOURCES 101
2.13 ASSUMPTIONS 101
3 EXECUTIVE SUMMARY 102
4 PREMIUM INSIGHTS 105
4.1 PESTEL ANALYSIS 106
4.2 PORTER'S 5 FORCES 107
5 INDUSTRY INSIGHTS 108
6 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS 109
7 MARKET OVERVIEW 111
7.1 DRIVERS 113
7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA 113
7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA 113
7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA 113
7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP 114
7.2 RESTRAINTS 114
7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS 114
7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS 115
7.3 OPPORTUNITIES 116
7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS 116
7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D 116
7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS 116
7.4 CHALLENGES 117
7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE 117
7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT 117
7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL) 118
8 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE 119
8.1 OVERVIEW 120
8.2 IMAGING 123
8.2.1 COMPUTED TOMOGRAPHY (CT) 124
8.2.2 CHEST X-RAY 124
8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 124
8.2.4 ULTRASOUND 124
8.2.5 POSITRON EMISSION TOMOGRAPHY (PET) 124
8.3 BIOPSY 124
8.3.1 EXCISIONAL OR INCISIONAL BIOPSY 125
8.3.2 CORE NEEDLE BIOPSY 125
8.4 IMMUNOHISTOCHEMISTRY 125
8.5 BIOMARKER TEST 126
8.5.1 BETA 2-M 127
8.5.2 LDH 127
8.5.3 CA-125 127
8.5.4 TP53 127
8.5.5 NPM1 128
8.5.6 OTHERS 128
8.6 GENETIC TEST 128
8.7 CYTOGENETICS 128
8.8 LUMBAR PUNCTURE (SPINAL TAP) 129
8.9 BLOOD TEST 130
8.10 CYTOCHEMISTRY 130
8.11 OTHERS 131
9 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE 132
9.1 OVERVIEW 133
9.2 AGGRESSIVE LYMPHOMAS 135
9.2.1 DIFFUSE LARGE B CELL LYMPHOMA 136
- 9.2.1.1 INSTRUMENT BASED PRODUCTS 137
- 9.2.1.2 PLATFORM BASED PRODUCTS 137
- 9.2.1.3 KITS AND REAGENTS 137
- 9.2.1.4 OTHER CONSUMABLES 137
9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA 137
- 9.2.2.1 INSTRUMENT BASED PRODUCTS 138
- 9.2.2.2 PLATFORM BASED PRODUCTS 138
- 9.2.2.3 KITS AND REAGENTS 138
- 9.2.2.4 OTHER CONSUMABLES 138
9.2.3 MANTLE CELL LYMPHOMA 138
- 9.2.3.1 INSTRUMENT BASED PRODUCTS 139
- 9.2.3.2 PLATFORM BASED PRODUCTS 139
- 9.2.3.3 KITS AND REAGENTS 139
- 9.2.3.4 OTHER CONSUMABLES 139
9.2.4 PERIPHERAL T-CELL LYMPHOMA 139
- 9.2.4.1 INSTRUMENT BASED PRODUCTS 140
- 9.2.4.2 PLATFORM BASED PRODUCTS 140
- 9.2.4.3 KITS AND REAGENTS 140
- 9.2.4.4 OTHER CONSUMABLES 140
9.2.5 LYMPHOBLASTIC LYMPHOMA 140
- 9.2.5.1 INSTRUMENT BASED PRODUCTS 141
- 9.2.5.2 PLATFORM BASED PRODUCTS 141
- 9.2.5.3 KITS AND REAGENTS 141
- 9.2.5.4 OTHER CONSUMABLES 141
9.2.6 BURKITT LYMPHOMA 141
- 9.2.6.1 INSTRUMENT BASED PRODUCTS 142
- 9.2.6.2 PLATFORM BASED PRODUCTS 142
- 9.2.6.3 KITS AND REAGENTS 142
- 9.2.6.4 OTHER CONSUMABLES 142
9.3 INDOLENT LYMPHOMAS 142
9.3.1 FOLLICULAR LYMPHOMA 143
- 9.3.1.1 INSTRUMENT BASED PRODUCTS 144
- 9.3.1.2 PLATFORM BASED PRODUCTS 144
- 9.3.1.3 KITS AND REAGENTS 144
- 9.3.1.4 OTHER CONSUMABLES 144
9.3.2 CUTANEOUS T-CELL LYMPHOMA 144
- 9.3.2.1 INSTRUMENT BASED PRODUCTS 145
- 9.3.2.2 PLATFORM BASED PRODUCTS 145
- 9.3.2.3 KITS AND REAGENTS 145
- 9.3.2.4 OTHER CONSUMABLES 145
9.3.3 MARGINAL ZONE B CELL LYMPHOMA 145
- 9.3.3.1 INSTRUMENT BASED PRODUCTS 146
- 9.3.3.2 PLATFORM BASED PRODUCTS 146
- 9.3.3.3 KITS AND REAGENTS 146
- 9.3.3.4 OTHER CONSUMABLES 146
9.3.4 LYMPHOPLASMACYTIC LYMPHOMA 146
- 9.3.4.1 INSTRUMENT BASED PRODUCTS 147
- 9.3.4.2 PLATFORM BASED PRODUCTS 147
- 9.3.4.3 KITS AND REAGENTS 147
- 9.3.4.4 OTHER CONSUMABLES 147
9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA 147
- 9.3.5.1 INSTRUMENT BASED PRODUCTS 148
- 9.3.5.2 PLATFORM BASED PRODUCTS 148
- 9.3.5.3 KITS AND REAGENTS 148
- 9.3.5.4 OTHER CONSUMABLES 148
10 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION 149
10.1 OVERVIEW 150
10.2 SCREENING 152
10.2.1 INSTRUMENT BASED PRODUCTS 153
10.2.2 PLATFORM BASED PRODUCTS 153
10.2.3 KITS AND REAGENTS 154
10.2.4 OTHER CONSUMABLES 154
10.3 DIAGNOSTIC AND PREDICTIVE 154
10.3.1 INSTRUMENT BASED PRODUCTS 155
10.3.2 PLATFORM BASED PRODUCTS 155
10.3.3 KITS AND REAGENTS 155
10.3.4 OTHER CONSUMABLES 155
10.4 PROGNOSTIC 155
10.4.1 INSTRUMENT BASED PRODUCTS 156
10.4.2 PLATFORM BASED PRODUCTS 156
10.4.3 KITS AND REAGENTS 156
10.4.4 OTHER CONSUMABLES 157
10.5 RESEARCH 157
10.5.1 INSTRUMENT BASED PRODUCTS 158
10.5.2 PLATFORM BASED PRODUCTS 158
10.5.3 KITS AND REAGENTS 158
10.5.4 OTHER CONSUMABLES 158
11 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE 159
11.1 OVERVIEW 160
11.2 STAGE IV 162
11.3 STAGE I 163
11.4 STAGE III 164
11.5 STAGE II 165
11.6 STAGE 0 166
12 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY 167
12.1 OVERVIEW 168
12.2 FLUORESCENT IN SITU HYBRIDIZATION 170
12.3 NEXT GENERATION SEQUENCING 171
12.4 FLUORIMMUNOASSAY 172
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 173
12.6 IMMUNOHISTOLOCHEMICAL 173
12.7 OTHER 174
13 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT 175
13.1 OVERVIEW 176
13.2 INSTRUMENT BASED PRODUCTS 178
13.2.1 IMAGING 179
13.2.2 BIOPSY 179
13.3 PLATFORM BASED PRODUCTS 180
13.3.1 NEXT-GENERATION SEQUENCING 181
13.3.2 MICROARRAYS 181
13.3.3 PCR 181
13.3.4 OTHERS 181
13.4 KITS AND REAGENTS 181
13.4.1 NON-HODGKIN LYMPHOMA PANELS 182
13.4.2 IMMUNOHISTOCHEMISTRY STAINS 182
13.4.3 OTHERS 182
13.5 OTHER CONSUMABLES 183
14 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER 184
14.1 OVERVIEW 185
14.2 HOSPITALS 187
14.3 DIAGNOSTIC CENTERS 188
14.4 CANCER RESEARCH CENTERS 189
14.5 ACADEMIC INSTITUTES 190
14.6 AMBULATORY SURGICAL CENTERS 190
14.7 OTHERS 191
15 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 192
15.1 OVERVIEW 193
15.2 DIRECT TENDER 195
15.3 RETAIL SALES 196
15.4 OTHERS 197
16 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION 198
16.1 ASIA-PACIFIC 199
16.1.1 CHINA 219
16.1.2 JAPAN 233
16.1.3 INDIA 247
16.1.4 AUSTRALIA 261
16.1.5 SOUTH KOREA 275
16.1.6 INDONESIA 289
16.1.7 PHILIPPINES 303
16.1.8 THAILAND 317
16.1.9 MALAYSIA 331
16.1.10 VIETNAM 345
16.1.11 SINGAPORE 358
16.1.12 REST OF ASIA-PACIFIC 372
17 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 373
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 373
18 SWOT ANALYSIS 374
19 ASIA PACIFIC NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET 375
19.1 CANON MEDICAL SYSTEMS CORPORATION 375
19.1.1 COMPANY SNAPSHOT 375
19.1.2 REVENUE ANALYSIS 375
19.1.3 COMPANY SHARE ANALYSIS 376
19.1.4 PRODUCT PORTFOLIO 376
19.1.5 RECENT DEVELOPMENT 376
19.2 KONINKLIJKE PHILIPS N.V 377
19.2.1 COMPANY SNAPSHOT 377
19.2.2 REVENUE ANALYSIS 377
19.2.3 COMPANY SHARE ANALYSIS 378
19.2.4 PRODUCT PORTFOLIO 378
19.2.5 RECENT DEVELOPMENTS 378
19.3 SIEMENS HEALTHCARE GMBH 379
19.3.1 COMPANY SNAPSHOT 379
19.3.2 REVENUE ANALYSIS 379
19.3.3 COMPANY SHARE ANALYSIS 380
19.3.4 PRODUCT PORTFOLIO 380
19.3.5 RECENT DEVELOPMENT 381
19.4 DANAHER 382
19.4.1 COMPANY SNAPSHOT 382
19.4.2 REVENUE ANALYSIS 382
19.4.3 COMPANY SHARE ANALYSIS 383
19.4.4 PRODUCT PORTFOLIO 383
19.4.5 RECENT DEVELOPMENTS 384
19.5 BIO-RAD LABORATORIES, INC 385
19.5.1 COMPANY SNAPSHOT 385
19.5.2 REVENUE ANALYSIS 385
19.5.3 COMPANY SHARE ANALYSIS 386
19.5.4 PRODUCT PORTFOLIO 386
19.5.5 RECENT DEVELOPMENT 386
19.6 AGILENT TECHNOLOGIES, INC 387
19.6.1 COMPANY PROFILE 387
19.6.2 REVENUE ANALYSIS 387
19.6.3 PRODUCT PORTFOLIO 388
19.6.4 RECENT DEVELOPMENT 388
19.7 CENTOGENE N.V 389
19.7.1 COMPANY SNAPSHOT 389
19.7.2 PRODUCT PORTFOLIO 389
19.7.3 RECENT DEVELOPMENT 389
19.8 F. HOFFMANN- LA ROCHE LTD 390
19.8.1 COMPANY SNAPSHOT 390
19.8.2 REVENUE ANALYSIS 390
19.8.3 PRODUCT PORTFOLIO 391
19.8.4 RECENT DEVELOPMENTS 391
19.9 GENERAL ELECTRIC COMPANY 392
19.9.1 COMPANY SNAPSHOT 392
19.9.2 REVENUE ANALYSIS 392
19.9.3 PRODUCT PORTFOLIO 393
19.9.4 RECENT DEVELOPMENTS 393
19.10 GENEDX, LLC 394
19.10.1 COMPANY SNAPSHOT 394
19.10.2 PRODUCT PORTFOLIO 394
19.10.3 RECENT DEVELOPMENT 394
19.11 GRAIL 395
19.11.1 COMPANY PROFILE 395
19.11.2 PRODUCT PORTFOLIO 395
19.11.3 RECENT DEVELOPMENT 395
19.12 HOLOGIC INC 396
19.12.1 COMPANY SNAPSHOT 396
19.12.2 REVENUE ANALYSIS 396
19.12.3 PRODUCT PORTFOLIO 397
19.12.4 RECENT DEVELOPMENT 397
19.13 INVITAE CORPORATION 398
19.13.1 COMPANY PROFILE 398
19.13.2 REVENUE ANALYSIS 398
19.13.3 PRODUCT PORTFOLIO 399
19.13.4 RECENT DEVELOPMENT 399
19.14 NEUSOFT CORPORATION 400
19.14.1 COMPANY SNAPSHOT 400
19.14.2 REVENUE ANALYSIS 400
19.14.3 PRODUCT PORTFOLIO 401
19.14.4 RECENT DEVELOPMENT 401
19.15 NEOGENOMICS LABORATORIES 402
19.15.1 COMPANY SNAPSHOT 402
19.15.2 REVENUE ANALYSIS 402
19.15.3 PRODUCT PORTFOLIO 403
19.15.4 RECENT DEVELOPMENTS 403
19.16 PERKINELMER INC 404
19.16.1 COMPANY PROFILE 404
19.16.2 REVENUE ANALYSIS 404
19.16.3 PRODUCT PORTFOLIO 405
19.16.4 RECENT DEVELOPMENT 405
19.17 QIAGEN 406
19.17.1 COMPANY SNAPSHOT 406
19.17.2 REVENUE ANALYSIS 406
19.17.3 PRODUCT PORTFOLIO 407
19.17.4 RECENT DEVELOPMENT 407
19.18 SYSMEX CORPORATION 408
19.18.1 COMPANY SNAPSHOT 408
19.18.2 REVENUE ANALYSIS 408
19.18.3 PRODUCT PORTFOLIO 409
19.18.4 RECENT DEVELOPMENTS 409
20 QUESTIONNAIRE 410
21 RELATED REPORTS 414